Clinical features of primary biliary cholangitis patients with negative or positive anti-mitochondrial antibody： A comparative study
- VernacularTitle:抗线粒体抗体阴性与阳性原发性胆汁性胆管炎患者临床特征比较
- Author:
Kexin QIAO
1
;
Guiqin ZHOU
1
;
Yaxing LIU
2
;
Ying FENG
1
;
Yao LIU
1
;
Bin LI
1
;
Xianbo WANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Primary Biliary Cholangitis; Antimitochondrial Antibody; Globulin; Prealbumin
- From: Journal of Clinical Hepatology 2024;40(9):1778-1784
- CountryChina
- Language:Chinese
- Abstract: ObjectiveTo investigate the differences in clinical features between the primary biliary cholangitis （PBC） patients with negative or positive anti-mitochondrial antibody （AMA） by analyzing related immune and biochemical parameters. MethodsThis study was conducted among the patients who attended Beijing Ditan Hospital， Capital Medical University， from January 2013 to December 2022 and were diagnosed with PBC， and they were divided into AMA negative group with 139 patients （24.5%） and AMA positive group with 428 patients （75.5%）. Propensity score matching at a ratio of 1∶1 was performed with age and sex as matching factors and a matching tolerance of 0.06. Liver function， coagulation， and immune parameters on admission were analyzed， as well as the changes in liver function and other indicators after 6 months of treatment and the response to ursodeoxycholic acid （UDCA） at 6 and 12 months of treatment. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data between two groups. ResultsThere were 139 AMA-negative PBC patients and 139 AMA-positive PBC patients after propensity score matching. Compared with the AMA positive group on admission， the AMA negative group had significantly lower levels of direct bilirubin and globulin （Glo） and significantly higher levels of albumin， albumin/globulin ratio， prealbumin， and fibrinogen （all P<0.05）. After 6 months of UDCA treatment， there were significant differences in Glo and prealbumin between the AMA negative group and the AMA positive group （P<0.05）. Both the AMA negative group and the AMA positive group had an increase in prealbumin after 6 months of treatment， and the AMA negative group had a significantly greater increase than the AMA positive group （U=41.00， P=0.015）. After UDCA treatment for 6 and 12 months， there was no significant difference in treatment response to UDCA between the AMA negative group and the AMA positive group （all P>0.05）. ConclusionAfter matching for age and sex， compared with the AMA-positive PBC patients， the AMA-negative PBC patients tend to have a milder degree of liver inflammation and damage， significantly greater improvements in inflammation and liver synthesis ability after UDCA treatment， and better response to UDCA.
